Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Dipharma
Dipharma
Activities:
Ingredients
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Manufacturing
Dipharma expands CDMO offering with new QC lab in the US
New lab has enabled Italy-based Dipharma to now offer full services from discovery to marketed drugs
Manufacturing
Dipharma Francis Srl sell Amino Chemicals to ABA Chemicals
Dipharma Francis Srl, a European manufacturer of Active Pharmaceutical Ingredients, completed the sale of its subsidiary Amino Chemicals, based in Malta, to ABA Chemicals Corporation, China
Research & Development
New room-temperature stable Carglunic acid tablets
Carglumic acid is a therapeutic tool in the management of inborn metabolic disorders affecting the urea cycle
Pharmaceutical
Disanit authorised for marketing in Europe
Dipharma's Disanit (Nitisinone capsules 2, 5 and 10mg) is now under marketing authorisation (MA) evaluation in the EU.
Distribution
Dipharma and Alvogen launch Diterin in South Korea
First drug commercially available for the treatment of hyperphenylalaninemia due to phenylketonuria
Subscribe now